Geriatric Research, Education and Clinical Center (GRECC), VA Puget Sound Health Care System, Seattle, WA, 98108, USA.
Yale University, New Haven, CT, 06520, USA.
Curr Oncol Rep. 2017 Jan;19(1):3. doi: 10.1007/s11912-017-0562-0.
Cachexia is a metabolic syndrome driven by inflammation and characterized by loss of muscle with or without loss of fat mass. In cancer cachexia, the tumor burden and host response induce increased inflammation, decreased anabolic tone, and suppressed appetite leading to the clinical presentation of reduced body weight and quality of life (QOL). There is no approved treatment for cancer cachexia, and commonly used nutritional and anti-inflammatory strategies alone have proven ineffective for management of symptoms. Several other pharmacological agents are currently in development and have shown promise as a clinical strategy in early-phase trials. Recently, it has been proposed that multimodal strategies, with an anabolic focus, initiated early in the disease/treatment progression may provide the most therapeutic potential for symptom management. Here we review the data from recent clinical trials in cancer cachexia including pharmacological, exercise, and nutritional interventions.
恶病质是一种由炎症驱动的代谢综合征，其特征是肌肉流失，伴有或不伴有脂肪量减少。在癌症恶病质中，肿瘤负荷和宿主反应会导致炎症增加、合成代谢状态降低和食欲抑制，从而导致体重减轻和生活质量（QOL）下降的临床表现。目前尚无批准用于治疗癌症恶病质的方法，单独使用常用的营养和抗炎策略已被证明对症状管理无效。目前有几种其他药物正在研发中，并且在早期试验中已显示出作为临床策略的前景。最近，有人提出，在疾病/治疗进展早期启动的以合成代谢为重点的多模式策略可能为症状管理提供最大的治疗潜力。在此，我们回顾了近期癌症恶病质临床试验的数据，包括药物、运动和营养干预。
